Research programme: Parkinson's disease therapeutics - Panacea Pharmaceuticals

Drug Profile

Research programme: Parkinson's disease therapeutics - Panacea Pharmaceuticals

Alternative Names: PAN 572; PAN-408; PAN-527

Latest Information Update: 31 May 2010

Price : $50

At a glance

  • Originator Panacea Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 05 Sep 2006 This programme is still in active development for Parkinson's disease
  • 16 Oct 2001 Preclinical development for Parkinson's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top